OBIO

Over the past six months, OBIO's stock price has been impacted by several events. As of May 8, 2026, OBIO's stock was trading around $4.04, reflecting a 2.7% decrease since January 1, 2026. In May 2026, Orchestra BioMed received a $15 million investment from Ligand and a $20 million payment from Medtronic. In April 2026, the FDA granted Orchestra BioMed an additional Breakthrough Device Designation for its AVIM Therapy, and the company announced presentations of AVIM Therapy clinical and mechanistic data at the Heart Rhythm Society (HRS) 2026 Annual Meeting. In March 2026, Orchestra BioMed reported its full-year 2025 financial results and provided a fourth-quarter business update, reporting $0.26 earnings per share for the quarter, beating estimates of -$0.38. In February 2026, insider buying activity was noted, and Medtronic plc filed a Form 13G indicating ownership of 10,078,625 shares. News updates from Fintel were reported in December 2025. In November 2025, Fintel and Zacks reported news, and the company held a 3Q25 Corporate Update Call, with Perceptive Advisors LLC, Perceptive Life Sciences Master Fund Ltd, and Joseph Edelman filing a Form 13G indicating ownership of 5,679,480 shares.